Other languages Design Therapeutics, Inc.

Equities

DSGN

US25056L1035

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
4.49 ^USD	-1.32%		-4.26%	+69.43%

May. 08	Design Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 07	Piper Sandler Upgrades Design Therapeutics to Overweight From Neutral	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Design Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08
Sector Update: Health Care Stocks Ease Late Afternoon	Mar. 20
Sector Update: Health Care Stocks Down Wednesday Afternoon	Mar. 20
Design Therapeutics Stock Rises as RBC Says Q4 Results, Product Candidate Updates Show Progress	Mar. 20
Design Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19
Design Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 19
Design Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Insider Buy: Design Therapeutics	23-08-31
Design Therapeutics, Inc. Announces CEO Changes	23-08-25
Design Therapeutics, Inc. Announces Management Changes	23-08-25
Financial Sector Woes, Lackluster Chinese Data Weigh on US Equity Markets	23-08-15
Sector Update: Health Care Stocks Slip Pre-Bell Tuesday	23-08-15
Sentiment Subdued After Downbeat China Data, Pushing US Equity Futures Lower Pre-Bell	23-08-15
Sector Update: Health Care	23-08-15
Top Premarket Decliners	23-08-15
Design Therapeutics Reports DT-216 Well-Tolerated in Phase 1 Trial But Injection Site Reactions Observed	23-08-14
Design Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
Design Therapeutics, Inc. Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia	23-08-14
Design Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09
Design Therapeutics, Inc. to Present Preclinical Data on its GeneTAC(TM) Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023	23-04-24

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Design Therapeutics, Inc.

Equities

DSGN

US25056L1035

Other languages

Filters